CD274 and colorectal carcinoma: As reported in CRC phase II clinical trials setting, by Lee et al., (2015) after the administration of Pembrolizumab (an anti PD-L1 mAb), a partial objective response rate of 40% were observed in MSI compare to 0% MSS CRC patients.